Anterogen KRX:065660KOSDAQ
안트로젠 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days1
DART filings, 7 days1
Articles tracked5since Sep 11
In Q2 2026, Anterogen reported revenue of ₩2.2bn, up 16.5% year on year, and an operating loss of ₩478m. Anterogen (안트로젠) appeared in 1 Korean news article and 1 DART filing over the past seven days. Coverage peaked on Oct 21 with 2 articles. The most common catalyst was clinical & approvals (1).
Filing signals Clinical trial filing 4 quarters of losses Screener
Anterogen quarterly results separate, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩2.2bn | +16.5% | −₩478m margin −21.7% | −₩150m |
| Q1 2026 | ₩2.1bn | +32.5% | −₩1.1bn margin −51.8% | −₩882m |
| Q4 2025 derived | ₩2.0bn | +12.0% | −₩475m margin −23.7% | −₩506m |
| Q3 2025 | ₩2.0bn | +7.4% | −₩407m margin −19.9% | −₩79m |
| Q2 2025 | ₩1.9bn | +10.4% | −₩455m margin −24.1% | −₩90m |
| Q1 2025 | ₩1.6bn | +4.6% | −₩1.1bn margin −68.4% | −₩699m |
| Q4 2024 derived | ₩1.8bn | -1.1% | −₩1.3bn margin −71.3% | −₩1.0bn |
| Q3 2024 | ₩1.9bn | +18.3% | −₩639m margin −33.6% | −₩162m |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Anterogen top stories 2 weeks, by number of outlets
- 1
- 2
Latest Anterogen news Korean headlines
-
김미형 안트로젠 대표 “통증 완화 넘어 연골 재생…주사제로 가능성 봤다”
1 more on this story · 1 outlets
- 김미형 안트로젠 대표 “통증 완화 넘어 연골 재생…주사제로 가능성 봤다”이데일리 · Oct 21 07:04